Marietta, Ohio, August 14, 2020
ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB: PKTX), a clinical-stage biomedical company, today announced that due the results that AAGP® has achieved over the previous years, we are now moving into whole organ transplantation, open heart surgery and cardiac ischemia treatment testing.
“In our in vitro model of rat cardiomyocytes, pre-treatment with PKX-001 substantially increased cell survival under stress conditions (exposure to the lipotoxic fatty acid, palmitate and the anthracycline class of drug, doxorubicin). The mechanism of PKX-001 protective activity may in part be explained by its inhibitory effect on cysteine-type endopeptidase activity involved in the apoptotic signaling pathway. PKX-001 had no cytotoxic effect and minimally affected survival and normal functional activity of cardiomyocytes, both in vitro and ex vivo.” – Prof. Dr. Thomas Pulinilkunnil, Ph.D.
PKX-001 is the designation given to the lead drug product molecule of the AAGP® family.
This study is being led by Prof. Dr. Thomas Pulinilkunnil, Ph.D., Diabetes Canada Scholar, Associate Professor, Department of Biochemistry and Molecular Biology, Dalhousie University, Adjunct Professor, University of New Brunswick, Affiliate Scientist, Saint John Regional Hospital, Dalhousie Medicine New Brunswick (DMNB).
According to market research published by iHealthcareAnalyst, the global market for organ transplantation estimated to reach $51 billion by 2025, growing at a CAGR of 9.9% over the forecast period, driven by increasing incidence of organ failures, and rising demand for transplant products such as tissue products, immunosuppressants, and organ preservation solutions.
See the promising research of AAGP® and results to date
Visit our new website at ProtoKinetix.com for more information and to join our email list.
ProtoKinetix, Inc.